ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has told DirectorsTalk that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma
Commenting on the Interims and outlook Tim McCarthy, Chairman, said: “Successfully raising £8.4 million and commencing our pivotal Phase III Lupuzor™ trial are two significant milestones for ImmuPharma over the first
ImmuPharma’s Tim McCarthy discusses their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Chairman with Tim McCarthy talks with DirectorsTalk about the ongoing Phase III clinical trial of Lupuzor™. Tim talks about overall activity in the US, early traction in
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme
ImmuPharma’s Tim McCarthy discusses the latest update on their Lupuzor Phase III clinical trial in this exclusive interview with DirectorsTalk
ImmuPharma Plc (LON:IMM) Chairman Tim McCarthy talks with DirectorsTalk about the phase 3 trials of lupuzor being opened up to Mauritius. Tim explains why the site is being opened up,
Northland Capital partners view on Immupharma PLC: Mauritius has a high proportion of Lupus sufferers. The Mauritian Government’s strong interest in Lupuzor™ demonstrates how Lupus is an unmet medical
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased DirectorsTalk with a provide a further update on the progress of its Phase III clinical trial of Lupuzor(TM),
We initiate coverage for ImmuPharma plc (LON:IMM) * Blockbuster potential: We expect Lupuzor could achieve multi-billion dollar annual sales as a potential treatment for Lupus. The drug has also recently shown promise
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
